TABLE 2

FROM:

Bupropion for the Treatment of Methamphetamine Dependence

Ahmed M Elkashef, Richard A Rawson, Ann L Anderson, Shou-Hua Li, Tyson Holmes, Edwina V Smith, Nora Chiang, Roberta Kahn, Frank Vocci, Walter Ling, Valerie J Pearce, Michael McCann, Jan Campbell, Charles Gorodetzky, William Haning, Barry Carlton, Joseph Mawhinney and Dennis Weis

Table 2. NLMM Estimates for Per-Week Increment in Odds of a Non-Use Week, Bupropion vs Placebo, for 'Stratification' Subgroups

n	Subgroup	Odds of non-use week	p-value	Bonferroni-adjusted
47	Males, non-depressed, lower baseline use	1.39	7.7 10-8	0.00625
10	Males, some depression, lower baseline use	1.34	0.000094	0.00714
13	Females, non-depressed, lower baseline use	1.27	0.020	0.00833
1	Females, some depression, lower baseline use	1.23	0.113	0.01000
34	Males, non-depressed, higher baseline use	1.08	0.396	0.01250
10	Males, some depression, higher baseline use	1.05	0.935	0.01667
9	Females some depression, higher baseline use	0.96	0.967	0.02500
27	Females, non-depressed, higher baseline use	0.99	0.994	0.05000